First Trust Advisors LP Acquires New Holdings in Repligen Co. (NASDAQ:RGEN)

First Trust Advisors LP bought a new position in shares of Repligen Co. (NASDAQ:RGEN – Get Rating) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 45,467 shares of the biotechnology company’s stock, valued at approximately $8,507,000. First Trust Advisors LP owned 0.08% of Repligen at the end of the most recent reporting period.

Other institutional investors have also made changes to their positions in the company. Credit Suisse AG boosted its position in shares of Repligen by 1.5% during the 3rd quarter. Credit Suisse AG now owns 52,577 shares of the biotechnology company’s stock worth $9,837,000 after purchasing an additional 758 shares during the period. Amalgamated Bank lifted its stake in Repligen by 3.6% during the third quarter. Amalgamated Bank now owns 39,981 shares of the biotechnology company’s stock worth $7,481,000 after purchasing an additional 1,395 shares in the last quarter. Congress Wealth Management LLC DE boosted its position in shares of Repligen by 20.2% during the third quarter. Congress Wealth Management LLC DE now owns 7,042 shares of the biotechnology company’s stock worth $1,318,000 after buying an additional 1,185 shares during the period. UBS Asset Management Americas Inc. grew its stake in shares of Repligen by 1.4% in the second quarter. UBS Asset Management Americas Inc. now owns 164,356 shares of the biotechnology company’s stock valued at $26,691,000 after buying an additional 2,253 shares in the last quarter. Finally, MML Investors Services LLC raised its holdings in shares of Repligen by 14.8% in the 3rd quarter. MML Investors Services LLC now owns 11,061 shares of the biotechnology company’s stock valued at $2,070,000 after buying an additional 1,429 shares during the period. 91.00% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages recently commented on RGEN. SVB Leerink lowered their target price on Repligen from $230.00 to $200.00 and set an “outperform” rating for the company in a report on Friday, January 6th. Deutsche Bank Aktiengesellschaft began coverage on shares of Repligen in a research note on Tuesday, December 13th. They set a “hold” rating and a $180.00 target price on the stock. Royal Bank of Canada assumed coverage on shares of Repligen in a research report on Tuesday, December 6th. They issued a “sector perform” rating and a $190.00 price target for the company. KeyCorp cut their price objective on Repligen from $260.00 to $240.00 and set an “overweight” rating on the stock in a research report on Thursday, February 23rd. Finally, StockNews.com cut Repligen from a “hold” rating to a “sell” rating in a research note on Thursday, February 23rd. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat, Repligen presently has an average rating of “Moderate Buy” and a consensus target price of $216.86.

Repligen Trading Down 4.2 %

Shares of RGEN opened at $166.27 on Monday. The firm has a market capitalization of $9.24 billion, a price-to-earnings ratio of 51.16, a PEG ratio of 2.62 and a beta of 1.09. The firm’s fifty day simple moving average is $181.25 and its 200-day simple moving average is $187.08. Repligen Co. has a twelve month low of $137.21 and a twelve month high of $262.26.

Repligen (NASDAQ:RGEN – Get Rating) last posted its quarterly earnings results on Wednesday, February 22nd. The biotechnology company reported $0.68 earnings per share for the quarter, beating analysts’ consensus estimates of $0.58 by $0.10. The company had revenue of $186.80 million for the quarter, compared to analysts’ expectations of $184.41 million. Repligen had a return on equity of 10.31% and a net margin of 23.20%. Repligen’s quarterly revenue was up .2% on a year-over-year basis. During the same period last year, the firm earned $0.81 earnings per share. On average, analysts predict that Repligen Co. will post 2.64 earnings per share for the current fiscal year.

Repligen Profile

(Get Rating)

Repligen Corp. provides bioprocessing technologies and solutions used in the process of manufacturing biologic drugs. It serves through the following product lines: Chromatography, Filtration, Process Analytics, and Proteins. The Chromatography product includes a range of products used in the downstream purification and quality control of biological drugs.